On the stock market since 1981, it operates in the world of health and science. It has 10,000 employees. Now — the numbers.
This is an established company with proven profits.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The gap is $1.8B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
It pays out $17.74 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, HRC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HRC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.